Smith & NephewLSE:SN. +3.09%86 EBITDA Margin % is 25.85% as of Dec. 2025, which is 6% above its 10-year median of 24.34. GuruFocus rates LSE:SN. with a GF Score™ of 86/100 and a GF Value™ of £11.87 (Fairly Valued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Smith & Nephew ranks better than 84.31% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Smith & Nephew's EBITDA for the
six
months ended in Dec. 2025 was £619 Mil. Smith & Nephew's Revenue for the
six
months ended in Dec. 2025 was £2,393 Mil. Therefore, Smith & Nephew's EBITDA margin for the quarter that ended in Dec. 2025 was 25.85%.
Smith & Nephew (LSE:SN.) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Smith & Nephew EBITDA Margin % Related Terms
Smith & Nephew EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Smith & Nephew's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:SN. vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Smith & Nephew's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Smith & Nephew EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Smith & Nephew's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Smith & Nephew's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Smith & Nephew (LSE:SN.) has a EBITDA Margin % of 25.85% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Smith & Nephew and its competitors. This is near median its historical median of 24.34. Over the past decade, Smith & Nephew's EBITDA Margin % has ranged from 16.76 to 34.12. According to the industry distribution chart, Smith & Nephew ranks #128 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 15.7%.
Is Smith & Nephew's EBITDA Margin % too high?
Smith & Nephew's current EBITDA Margin % of 25.85% is near median its 10-year median of 24.34. Over the past 10 years, this metric has ranged from a low of 16.76 to a high of 34.12. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Smith & Nephew's value of 25.85% is 245.8% above this industry median. Based on the distribution chart, Smith & Nephew ranks #128 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Smith & Nephew has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Smith & Nephew's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Smith & Nephew ranks #128 out of 816 companies for EBITDA Margin %. This places Smith & Nephew in the top 16% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Smith & Nephew's value of 25.85% is 245.8% above this benchmark. Historically, Smith & Nephew's own EBITDA Margin % has ranged from 16.76 to 34.12 over the past decade. While the company's 10-year median is 24.34 vs. the industry median of 7.48, Smith & Nephew has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Smith & Nephew's current EBITDA Margin % of 25.85% is 245.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Smith & Nephew and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Smith & Nephew's current EBITDA Margin % is 25.85%, which is near median its own 10-year median of 24.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smith & Nephew stock overvalued right now?
Based on GuruFocus' analysis, Smith & Nephew (LSE:SN.) is currently considered Fairly Valued. The stock's GF Value™ is £11.87, compared to a current price of £11.53 — trading 2.9% below its estimated fair value. The current EBITDA Margin % is 25.85%, which is near median its 10-year median of 24.34 and 245.8% above the Medical Devices & Instruments industry median of 7.48. Smith & Nephew's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Smith & Nephew (LSE:SN.), the current EBITDA Margin % is 25.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Smith & Nephew (LSE:SN.) Overvalued in 2026?
Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued.
The current stock price of £11.53 is trading 2.9% below its estimated GF Value™ of £11.87.
GuruFocus considers Smith & Nephew to be Fairly Valued.
Key valuation signals for LSE:SN.:
EBITDA Margin %: 25.85% (near median its 10-year median of 24.34)
GF Value™: £11.87 vs. price of £11.53 (2.9% below fair value)
Industry Position: 245.8% above the Medical Devices & Instruments median (#128 of 816)
No single metric tells the full story. See the LSE:SN. stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
86GF Score
Get the complete analysis for LSE:SN.
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SN. has been successfully added to your 
